Antheia’s 2024 in Review: A Year Of Collaboration
As we reflect on 2024, it’s been a significant year of collaboration, with every Antheia employee and partner helping us move closer toward our mission of transforming pharmaceutical supply chains and ending essential medicine shortages. No one person, company, or organization can solve a daunting global problem like drug shortages alone, but we have made […]
Antheia Lands $12M with Second BioMaP Deal to Reshape U.S. Pharma
The company was awarded for its ability to outperform conventional manufacturing methods for critical pharmaceutical ingredients and rapidly reach a commercial scale in the U.S.
Antheia Secures Second Project Agreement with the BioMaP-Consortium Valued at up to $12M
Company awarded for its ability to outperform conventional manufacturing methods for critical pharmaceutical ingredients and rapidly reach commercial scale in the U.S.
InnovationRx: Venture Investments Into Biopharma And Medtech Reverse 2-Year Slide
Antheia, which is using fermentation to manufacture drug ingredients that are normally produced agriculturally, announced its first commercial delivery this week.
Antheia Fulfills First Commercial Delivery of Thebaine
Antheia, a pharmaceutical ingredient manufacturer, has delivered its first commercial order of thebaine to a leading pharmaceutical customer.
Antheia’s First Commercial Thebaine Delivery Sets New Standard in Pharmaceutical Biomanufacturing
This first commercial-scale thebaine delivery redefines essential medicine supply chains, supporting biomanufacturing’s future in pharma.
Antheia Marks Corporate Milestone with First Commercial Delivery of Thebaine
Company successfully fulfills its first customer order; continues commercial scale production of thebaine and advances other critical pharmaceutical ingredients.
Brewing Medicines with Synthetic Biology: Antheia’s Christina Smolke on Ending Drug Shortages
In this episode of the Grow Everything Biotech Podcast, Karl and Erum welcome Christina Smolke, CEO of Antheia and Professor at Stanford University, to discuss the rapid changes happening in biotech, particularly focusing on the biohacking community and decentralized science (DCI).
Pharma isn’t ready for OTC Narcan demand
Today’s blog will focus on Narcan, a critical opioid overdose rescue drug that is produced from thebaine, Antheia’s first commercial-scale, biomanufactured pharmaceutical ingredient. Read on for more on recent efforts to make Narcan available over the counter, as well as the challenges and opportunities this policy change presents for the pharma industry.
Introducing Ben Kotopka, Director of Data Science
Ben’s work enables teams across the business to track and make sense of more than a decade of R&D data.